Osteoporosis, a systemic skeletal disease characterized by reduced bone mass and microarchitectural deterioration, is a major public health issue. To optimize the management of osteoporosis, healthcare professionals need a comprehensive understanding of the disease and its management.
Osteoporosis is often silent until a fracture occurs. It is predominantly seen in postmenopausal women but can affect men and premenopausal women. Risk factors include age, family history, low body mass index, and lifestyle factors such as smoking and excessive alcohol consumption. Early identification and management can significantly reduce the risk of fractures.
Diagnosis is based on bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA). The World Health Organisation defines osteoporosis as a BMD 2.5 standard deviations below the young adult mean. Fracture risk assessment tools, such as FRAX, can also help identify high-risk individuals.
Management of osteoporosis involves lifestyle modifications, adequate calcium and vitamin D intake, and pharmacological therapy. First-line treatment options include bisphosphonates, denosumab, and selective estrogen receptor modulators. Anabolic agents like teriparatide and abaloparatide are used in severe cases. Treatment choice depends on the patient's risk profile and potential side effects.
Regular follow-up and monitoring are essential. BMD should be re-evaluated every 1-2 years. Treatment effectiveness can be assessed through changes in BMD, biochemical markers of bone turnover, and fracture incidence. Adherence to therapy is crucial for treatment success and should be regularly assessed.
Optimizing osteoporosis management requires a comprehensive approach, including understanding the disease, risk assessment, appropriate treatment, and diligent follow-up. By staying informed about the latest evidence and guidelines, healthcare professionals can contribute significantly to reducing the burden of this debilitating disease.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation